Compare LFT & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFT | PDSB |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.1M | 62.0M |
| IPO Year | N/A | 2015 |
| Metric | LFT | PDSB |
|---|---|---|
| Price | $1.04 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 160.3K | ★ 1.1M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 18.49% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $668.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $0.51 |
| 52 Week High | $2.65 | $1.90 |
| Indicator | LFT | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 38.14 | 52.44 |
| Support Level | $1.04 | $0.85 |
| Resistance Level | $1.40 | $1.47 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 19.23 | 32.00 |
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.